URGNライブシグナル | Getagraph.comで利益を最大化

売る 108527 min ago

@ $19.19

発行日: 14 2月 2024 @ 01:02

リターン: -26.27%

前回のシグナル: 2月 13 - 05:11

前回のシグナル: 買う

リターン: -0.20 %

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases...

Stats
本日の出来高	135 619
平均出来高	364 868
時価総額	482.83M
EPS	$0 ( 2024-03-21 )
次の収益日	( $-0.930 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.99
ATR14	$0.0290 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Schoenberg Mark	Sell	12 000	Ordinary Shares
2024-01-31	Kim Dong	Buy	3 333	Ordinary Shares
2022-03-25	Kim Dong	Buy	20 000	Stock Option (right to buy)
2024-02-01	Smith Jason Drew	Sell	3 328	Ordinary Shares
2024-02-01	Smith Jason Drew	Sell	1 248	Ordinary Shares

INSIDER POWER
58.85
Last 96 transactions
Buy: 1 308 776 \| Sell: 407 960

ボリューム相関

長: 0.26 (neutral)

短: -0.02 (neutral)

Signal:(62.511) Neutral

Urogen Pharma Ltd 相関

10 最も正の相関
SVAC	0.916
GOODM	0.907
TLGT	0.891
MTSL	0.871
NSTS	0.866
TTWO	0.86
LUNG	0.851
PAIC	0.851
RMNI	0.845
RCM	0.833

10 最も負の相関
LWAC	-0.955
SRAC	-0.919
AMRB	-0.902
LMRKN	-0.889
NETE	-0.881
KNSA	-0.847
UTHR	-0.847
RAVN	-0.84
OFS	-0.831
TECH	-0.828

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Urogen Pharma Ltd 相関 - 通貨/商品

0.18
( neutral )

0.13
( neutral )

0.00
( neutral )

-0.39
( neutral )

-0.17
( neutral )

0.09
( neutral )

Urogen Pharma Ltd 財務諸表

Annual	2023
収益:	$82.71M
総利益:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2023
収益:	$82.71M
総利益:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2022
収益:	$64.36M
総利益:	$56.70M (88.11 %)
EPS:	$-4.79

FY	2021
収益:	$48.04M
総利益:	$42.89M (89.27 %)
EPS:	$-4.96

Financial Reports:

No articles found.

Urogen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.